Premium
Newer Strategies for the Treatment of Heparin‐Induced Thrombocytopenia
Author(s) -
Warkentin Theodore E.,
Barkin Robert L.
Publication year - 1999
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.19.3.181.30928
Subject(s) - heparin induced thrombocytopenia , heparin , medicine , adverse effect , intensive care medicine , thrombin generation , platelet , immunology , thrombin
Treatment with heparin is associated with two types of thrombocytopenia. One is a mild, transient, nonimmune disorder, generally without adverse clinical consequence. The other, known as heparin‐induced thrombocytopenia (HIT), is a potentially serious, immunoglobulin‐mediated reaction with a paradoxic high risk of thromboembolic events. Various treatment options for HIT are discussed, with emphasis on pharmacologic approaches that control the increased thrombin generation characteristic of this disorder.